ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Exelixis Inc

Exelixis Inc (EXEL)

22.40
-0.15
(-0.67%)
Closed July 12 4:00PM
22.40
0.00
( 0.00% )
Pre Market: 4:00AM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
22.40
Bid
13.80
Ask
24.55
Volume
-
0.00 Day's Range 0.00
18.64 52 Week Range 24.34
Market Cap
Previous Close
22.40
Open
-
Last Trade
Last Trade Time
-
Financial Volume
-
VWAP
-
Average Volume (3m)
1,840,765
Shares Outstanding
291,292,704
Dividend Yield
-
PE Ratio
31.40
Earnings Per Share (EPS)
0.71
Revenue
1.83B
Net Profit
207.77M

About Exelixis Inc

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under... Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Headquarters
Wilmington, Delaware, USA
Founded
1970
Exelixis Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker EXEL. The last closing price for Exelixis was $22.40. Over the last year, Exelixis shares have traded in a share price range of $ 18.64 to $ 24.34.

Exelixis currently has 291,292,704 shares outstanding. The market capitalization of Exelixis is $6.52 billion. Exelixis has a price to earnings ratio (PE ratio) of 31.40.

Exelixis (EXEL) Options Flow Summary

Overall Flow

Bullish

Net Premium

60k

Calls / Puts

100.00%

Buys / Sells

0.00%

OTM / ITM

0.00%

Sweeps Ratio

0.00%

EXEL Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.241.0830324909722.1622.74521.86131532922.23911248CS
40.773.5598705501621.6322.74521.36162754722.18902328CS
12-0.16-0.70921985815622.5623.8920.14184076521.92763412CS
26-0.2-0.88495575221222.624.0720.015205741622.12084597CS
523.0115.52346570419.3924.3418.64217918221.79520152CS
1564.7927.200454287317.6124.3414.87231887219.60144034CS
2601.336.312292358821.0727.913.67242717720.10664372CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0
AAGRAfrican Agriculture Holdings Inc
$ 0.179
(0.00%)
0
AADRAdvisorShares Dorsey Wright ADR ETF
$ 63.60
(0.00%)
0
AADIAadi Bioscience Inc
$ 1.55
(0.00%)
0
AACIArmada Acquisition Corporation I
$ 11.6001
(0.00%)
0
AACGATA Creativity Global
$ 0.83
(0.00%)
0

EXEL Discussion

View Posts
harry crumb harry crumb 1 year ago
Wow glad we held this! Wealth$$$$$
πŸ‘οΈ0
sanctuary sanctuary 3 years ago
Analyst Ratings For Exelixis
11/3/21 12:43 PM ET (Benzinga)Print
Over the past 3 months, 5 analysts have published their opinion on Exelixis (NASDAQ:EXEL) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

BullishSomewhat BullishIndifferentSomewhat BearishBearish

Total Ratings32000

Last 30D11000

1M Ago11000

2M Ago10000

3M Ago00000

These 5 analysts have an average price target of $35.2 versus the current price of Exelixis at $19.505, implying upside.

Below is a summary of how these 5 analysts rated Exelixis over the past 3 months. The greater the number of bullish ratings, the more positive analysts are on the stock and the greater the number of bearish ratings, the move negative analysts are on the stock

This current average has decreased by 14.15% from the previous average price target of $41.0.

What Are Analyst Ratings?

Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.

Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.

Latest Ratings for EXEL DateFirmActionFromTo

Nov 2021RBC CapitalMaintainsOutperform Nov 2021HC Wainwright & Co.MaintainsBuy Nov 2021OppenheimerMaintainsOutperform
πŸ‘οΈ0
Jaydixson1 Jaydixson1 4 years ago
Exel looking good
πŸ‘οΈ0
harry crumb harry crumb 4 years ago
This is a winner! $$$$
πŸ‘οΈ0
whytestocks whytestocks 4 years ago
News; $EXEL Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020

- Online event will be accessible at www.exelixis.com - Exelixis, Inc. (Nasdaq: EXEL) today announced it will host an investor briefing to discuss data presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020. The online-only event will be held following ...

Got this from EXEL - Exelixis to Host Investor Briefing to Discuss Data Presented at the European Society for Medical Oncology Virtual Congress 2020
πŸ‘οΈ0
whytestocks whytestocks 4 years ago
Just In: $EXEL Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash

When the S&P 500 lost 4.3% in two days last week, some of our bull market enthusiasm may have faded. And many of us were probably thinking back to the March market crash . Are we prepared for the next one? It may not be right around the corner, but it's never too early to prepare for oppo...

Find out more EXEL - Got $5,000? 3 Surefire Stocks to Buy Ahead of the Next Market Crash
πŸ‘οΈ0
vinmantoo vinmantoo 4 years ago
EXEL +1.71 really hard move up in final minutes don't see any news?

Anyone know why?

Bueller?


It about freaking time! My question is more along the lines of "why did EXEL drift down so much the past month or two?"
πŸ‘οΈ0
Beerworld Beerworld 4 years ago
a Lot of volume on those closing buys
πŸ‘οΈ0
girlfriend girlfriend 4 years ago
EXEL +1.71 really hard move up in final minutes don't see any news?

Anyone know why?

Bueller?
πŸ‘οΈ0
harry crumb harry crumb 4 years ago
Could be a better play here than acad, playing both for long term $$
πŸ‘οΈ0
harry crumb harry crumb 4 years ago
When cabo an cobi move to the next phase! $$$$$
πŸ‘οΈ0
girlfriend girlfriend 4 years ago
Mr. Crumb what is the next catalyst for EXEL? You still thinking $50?
πŸ‘οΈ0
harry crumb harry crumb 4 years ago
Might be a sell at 30+ here, will monitor news
πŸ‘οΈ0
harry crumb harry crumb 4 years ago
Told everyone 2 yrs ago to hold an accumulate. This is the next acad! Yes 50+ is a great target. $$$
πŸ‘οΈ0
vinmantoo vinmantoo 4 years ago
Going to $50!!!

That is possible with a buyout.
πŸ‘οΈ0
sorkin sorkin 4 years ago
Going to $50!!!
πŸ‘οΈ0
fung_derf fung_derf 4 years ago
I see Motley Fool recommending this stock, but I don't see why. What I see is a stock that can't break through it's resistance and earnings are falling.
What am I missing here?
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
An opportunity to add is here folks. $$$$
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
Going to buy more. Longvan strong for buyout in the 30’s. This is a copycat of aria! $$$$
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
Buy these up people, buyout coming!
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
All that means is this company will be sold at some point! Should be in excess of the 35 area
πŸ‘οΈ0
tpg tpg 5 years ago
Approval of the proposal of Exelixis’ Board of Directors to amend Exelixis’ Amended and Restated Certificate of Incorporation to declassify the Board of Directors to provide for annual elections by the 2020 Annual Meeting of Stockholders.
What that mean?
If you can explain
Appreciate it
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
Big money made here! Holding a core in the event of a 30+ buyout! $$$$$
πŸ‘οΈ0
harry crumb harry crumb 5 years ago
Congrats to all who bought more or consolidated around the 14 area. Wealth! $$$$
πŸ‘οΈ0
rabbit67 rabbit67 6 years ago
They approved 5 or 6 on the 10th...and previous days..jus sayin...who knows huh in this day an age
πŸ‘οΈ0
robtewms robtewms 6 years ago
Be careful. Powers that be take it lower just before Options expiration then take it back up.
πŸ‘οΈ0
harry crumb harry crumb 6 years ago
Hhhmmmm, time to double up
πŸ‘οΈ0
Ortho91 Ortho91 6 years ago
Yes pdufa still on board for January
πŸ‘οΈ0
harry crumb harry crumb 6 years ago
Nice pop today, back to the 20+ it should go
πŸ‘οΈ0
practicaltactical practicaltactical 6 years ago
I own a few hundred shares, is their Jan 14th 2019 pdufa still on
or did the news come early? I just read an article the stated just that but there is no date when the article was written.
πŸ‘οΈ0
biotechrocks biotechrocks 6 years ago
ESMO underway and EXEL has already presented BIG results from two trials. Share price will be much higher by the time ESMO ends and then even higher after Nov 1st earnings which will be another huge EPS beat (given the revenue growth; royalties coming in and milestone payments during the qtr).

Personally added a bunch more during the big negative days this week as well a little more on Friday. Couldn't be more happier given the bright future ahead for EXEL in 2019. Should be on path to set new 52 week high after more positive news in 2018 and then the BIG start in 2019 with the HCC approval and another big Qtr'ly release in early Feb. Lastly, remember there are another 70+ trials ongoing (mono and combo) which will have output in 2019 as well.
πŸ‘οΈ0
harry crumb harry crumb 6 years ago
Still long here. Patience as usual. $$$
πŸ‘οΈ0
biotechrocks biotechrocks 6 years ago
Up 8% to 22.15 on stellar earnings. Should reach $25 very quickly and then tutes jump in and we see new 52 week high of $32.5 plus
πŸ‘οΈ0
biotechrocks biotechrocks 6 years ago
Killer earnings means $25 plus here we come! Glad I jumped in heavy and added a bunch more at $20.50
πŸ‘οΈ0
biotechrocks biotechrocks 6 years ago
Looks like a great entry point at $20.50 . Jumped in with both feet as this company should be much higher in share price. Looking forward to earnings and future HCC news!
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://www.healio.com/endocrinology/adrenal/news/online/%7B3a878803-7fd1-417e-9946-69ac07c76b14%7D/cancer-drug-may-benefit-patients-with-metastatic-pheochromocytoma-paraganglioma
πŸ‘οΈ0
Runners123 Runners123 6 years ago
People need to start reading and sharing these posts

https://www.healio.com/endocrinology/adrenal/news/online/%7B3a878803-7fd1-417e-9946-69ac07c76b14%7D/cancer-drug-may-benefit-patients-with-metastatic-pheochromocytoma-paraganglioma
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://seekingalpha.com/article/4175380-may-best-time-pick-exelixis-2018
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://www.streetinsider.com/Analyst+Comments/Oppenheimer+Reiterates+Outperform+on+Exelixis+%28EXEL%29/14207378.html
πŸ‘οΈ0
Runners123 Runners123 6 years ago
Up over 13% from last Thurs dum and going back to $30 as people ignore it.
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://www.ncbi.nlm.nih.gov/pubmed/29393024
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://finance.yahoo.com/news/exelixis-partner-ipsen-announces-european-050100199.html
πŸ‘οΈ0
Runners123 Runners123 6 years ago
https://finance.yahoo.com/news/options-traders-betting-big-move-124012218.html
πŸ‘οΈ0
Runners123 Runners123 6 years ago
Drugs making money and the technicals are better than most looking for $25 - $30 in 30 days.
πŸ‘οΈ0
Runners123 Runners123 6 years ago
Nowhere to go but up from here.
πŸ‘οΈ0
Runners123 Runners123 6 years ago
Intro needs to be updated.
πŸ‘οΈ0
styl styl 6 years ago
Is it worth buying option leaps in this stock or has it made its huge runs already. ?
πŸ‘οΈ0
Beerworld Beerworld 6 years ago
https://seekingalpha.com/news/3344505-roche-suspends-mid-stage-study-tecentriq-cotellic-combo-late-stage-crc-exelixis-7-percent
πŸ‘οΈ0
D E D E 6 years ago
Can you post more details, thsnks
πŸ‘οΈ0
Beerworld Beerworld 6 years ago
Roche suspended a test
πŸ‘οΈ0

Your Recent History

Delayed Upgrade Clock